世界の良性前立腺肥大症(BPH)治療薬市場2020:製造企業別、地域別、種類別、用途別、市場予測2025

GlobalInfoResearchが発行した調査報告書(GIR20OC01758)
◆英語タイトル:Global Benign Prostatic Hyperplasia (BPH) Medication Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025
◆商品コード:GIR20OC01758
◆発行会社(リサーチ会社):GlobalInfoResearch
◆発行日:2020年10月(※2024年版があります。お問い合わせください。)
◆ページ数:152
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医薬品・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,480 ⇒換算¥515,040見積依頼/購入/質問フォーム
Multi User(10名様閲覧用)USD5,220 ⇒換算¥772,560見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalInfoResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。

本書では、良性前立腺肥大症(BPH)治療薬の世界市場を調査対象にし、良性前立腺肥大症(BPH)治療薬の市場概要、メーカー情報、メーカー別販売量・売上・市場シェア、地域別市場分析(北米、アメリカ、ヨーロッパ、アジア、日本、中国、南米、中東・アフリカ)、種類別分析(5-α-レダクターゼ阻害剤、ベータ遮断薬、植物薬、漢方薬)、用途別分析(病院薬局、小売薬局、オンライン薬局)、市場予測(2021年~2025年)、販売チャンネル・代理店分析情報などを整理しました。
・市場概要
・メーカー情報:Astellas Pharma、Valeant Pharmaceuticals、Sanofi、Eli Lilly、Bristol-Myers Squibb、GlaxoSmithKline、Foresee Pharmaceuticals、Bayer HealthCare、ADC Therapeutics、Endo Pharmaceuticals、Urologixs、BHR Pharma、Merck、Sanpower Group、Agennix、Teva Pharmaceutical Industries、Novartis、Boehringer Ingelheim、ANI Pharmaceuticals、Advaxis、Spectrum Pharmaceuticals、Eisai、Nymox Pharmaceutical、Madrigal Pharmaceuticals、LIDDS、Ferring、Takeda Pharmaceuticals、IO THERAPEUTICS
・メーカー別販売量、売上、市場シェア
・良性前立腺肥大症(BPH)治療薬の地域別市場分析
・良性前立腺肥大症(BPH)治療薬の北米市場規模2015-2020:アメリカ、カナダ、メキシコ
・良性前立腺肥大症(BPH)治療薬のヨーロッパ市場規模2015-2020:ドイツ、イギリス、フランス、ロシアなど
・良性前立腺肥大症(BPH)治療薬のアジア市場規模2015-2020:日本、中国、韓国、インド、東南アジアなど
・良性前立腺肥大症(BPH)治療薬の南米市場規模2015-2020:ブラジル、アルゼンチンなど
・良性前立腺肥大症(BPH)治療薬の中東・アフリカ市場規模2015-2020:サウジアラビア、トルコ、エジプト、南アフリカなど
・良性前立腺肥大症(BPH)治療薬の種類別市場規模2015-2020:5-α-レダクターゼ阻害剤、ベータ遮断薬、植物薬、漢方薬
・良性前立腺肥大症(BPH)治療薬の用途別市場規模2015-2020:病院薬局、小売薬局、オンライン薬局
・良性前立腺肥大症(BPH)治療薬の世界市場予測2021-2025:地域別、種類別、用途別
・販売チャンネル・代理店分析
・調査の結果・結論
【レポートの概要】

Market Overview
The global Benign Prostatic Hyperplasia (BPH) Medication market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.

The Benign Prostatic Hyperplasia (BPH) Medication market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentation
Benign Prostatic Hyperplasia (BPH) Medication market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Benign Prostatic Hyperplasia (BPH) Medication market has been segmented into
5-Alpha-Reductase Inhibitors
Beta-Blockers
Botanicals and Traditional Chinese Medicine

By Application, Benign Prostatic Hyperplasia (BPH) Medication has been segmented into:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Benign Prostatic Hyperplasia (BPH) Medication market presented in the report. This section sheds light on the sales growth of different regional and country-level Benign Prostatic Hyperplasia (BPH) Medication markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Benign Prostatic Hyperplasia (BPH) Medication market.

The report offers in-depth assessment of the growth and other aspects of the Benign Prostatic Hyperplasia (BPH) Medication market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, etc.)
Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)

Competitive Landscape and Benign Prostatic Hyperplasia (BPH) Medication Market Share Analysis
Benign Prostatic Hyperplasia (BPH) Medication competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Benign Prostatic Hyperplasia (BPH) Medication sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Benign Prostatic Hyperplasia (BPH) Medication sales, revenue and market share for each player covered in this report.

The major players covered in Benign Prostatic Hyperplasia (BPH) Medication are:
Astellas Pharma
Valeant Pharmaceuticals
Sanofi
Eli Lilly
Bristol-Myers Squibb
GlaxoSmithKline
Foresee Pharmaceuticals
Bayer HealthCare
ADC Therapeutics
Endo Pharmaceuticals
Urologixs
BHR Pharma
Merck
Sanpower Group
Agennix
Teva Pharmaceutical Industries
Novartis
Boehringer Ingelheim
ANI Pharmaceuticals
Advaxis
Spectrum Pharmaceuticals
Eisai
Nymox Pharmaceutical
Madrigal Pharmaceuticals
LIDDS
Ferring
Takeda Pharmaceuticals
IO THERAPEUTICS

Among other players domestic and global, Benign Prostatic Hyperplasia (BPH) Medication market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.

The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Benign Prostatic Hyperplasia (BPH) Medication product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Benign Prostatic Hyperplasia (BPH) Medication, with price, sales, revenue and global market share of Benign Prostatic Hyperplasia (BPH) Medication in 2018 and 2019.
Chapter 3, the Benign Prostatic Hyperplasia (BPH) Medication competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Benign Prostatic Hyperplasia (BPH) Medication breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 12, Benign Prostatic Hyperplasia (BPH) Medication market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.
Chapter 13, 14 and 15, to describe Benign Prostatic Hyperplasia (BPH) Medication sales channel, distributors, customers, research findings and conclusion, appendix and data source.

【レポートの目次】

Table of Contents

1 Market Overview
1.1 Benign Prostatic Hyperplasia (BPH) Medication Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 5-Alpha-Reductase Inhibitors
1.2.3 Beta-Blockers
1.2.4 Botanicals and Traditional Chinese Medicine
1.3 Market Analysis by Application
1.3.1 Overview: Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Overview of Global Benign Prostatic Hyperplasia (BPH) Medication Market
1.4.1 Global Benign Prostatic Hyperplasia (BPH) Medication Market Status and Outlook (2015-2025)
1.4.2 North America (United States, Canada and Mexico)
1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)
1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.5 South America, Middle East & Africa
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Astellas Pharma
2.1.1 Astellas Pharma Details
2.1.2 Astellas Pharma Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Astellas Pharma SWOT Analysis
2.1.4 Astellas Pharma Product and Services
2.1.5 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.2 Valeant Pharmaceuticals
2.2.1 Valeant Pharmaceuticals Details
2.2.2 Valeant Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Valeant Pharmaceuticals SWOT Analysis
2.2.4 Valeant Pharmaceuticals Product and Services
2.2.5 Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.3 Sanofi
2.3.1 Sanofi Details
2.3.2 Sanofi Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Sanofi SWOT Analysis
2.3.4 Sanofi Product and Services
2.3.5 Sanofi Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.4 Eli Lilly
2.4.1 Eli Lilly Details
2.4.2 Eli Lilly Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Eli Lilly SWOT Analysis
2.4.4 Eli Lilly Product and Services
2.4.5 Eli Lilly Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.5 Bristol-Myers Squibb
2.5.1 Bristol-Myers Squibb Details
2.5.2 Bristol-Myers Squibb Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Bristol-Myers Squibb SWOT Analysis
2.5.4 Bristol-Myers Squibb Product and Services
2.5.5 Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.6 GlaxoSmithKline
2.6.1 GlaxoSmithKline Details
2.6.2 GlaxoSmithKline Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 GlaxoSmithKline SWOT Analysis
2.6.4 GlaxoSmithKline Product and Services
2.6.5 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.7 Foresee Pharmaceuticals
2.7.1 Foresee Pharmaceuticals Details
2.7.2 Foresee Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Foresee Pharmaceuticals SWOT Analysis
2.7.4 Foresee Pharmaceuticals Product and Services
2.7.5 Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.8 Bayer HealthCare
2.8.1 Bayer HealthCare Details
2.8.2 Bayer HealthCare Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Bayer HealthCare SWOT Analysis
2.8.4 Bayer HealthCare Product and Services
2.8.5 Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.9 ADC Therapeutics
2.9.1 ADC Therapeutics Details
2.9.2 ADC Therapeutics Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 ADC Therapeutics SWOT Analysis
2.9.4 ADC Therapeutics Product and Services
2.9.5 ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.10 Endo Pharmaceuticals
2.10.1 Endo Pharmaceuticals Details
2.10.2 Endo Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Endo Pharmaceuticals SWOT Analysis
2.10.4 Endo Pharmaceuticals Product and Services
2.10.5 Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.11 Urologixs
2.11.1 Urologixs Details
2.11.2 Urologixs Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 Urologixs SWOT Analysis
2.11.4 Urologixs Product and Services
2.11.5 Urologixs Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.12 BHR Pharma
2.12.1 BHR Pharma Details
2.12.2 BHR Pharma Major Business and Total Revenue (Financial Highlights) Analysis
2.12.3 BHR Pharma SWOT Analysis
2.12.4 BHR Pharma Product and Services
2.12.5 BHR Pharma Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.13 Merck
2.13.1 Merck Details
2.13.2 Merck Major Business and Total Revenue (Financial Highlights) Analysis
2.13.3 Merck SWOT Analysis
2.13.4 Merck Product and Services
2.13.5 Merck Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.14 Sanpower Group
2.14.1 Sanpower Group Details
2.14.2 Sanpower Group Major Business and Total Revenue (Financial Highlights) Analysis
2.14.3 Sanpower Group SWOT Analysis
2.14.4 Sanpower Group Product and Services
2.14.5 Sanpower Group Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.15 Agennix
2.15.1 Agennix Details
2.15.2 Agennix Major Business and Total Revenue (Financial Highlights) Analysis
2.15.3 Agennix SWOT Analysis
2.15.4 Agennix Product and Services
2.15.5 Agennix Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.16 Teva Pharmaceutical Industries
2.16.1 Teva Pharmaceutical Industries Details
2.16.2 Teva Pharmaceutical Industries Major Business and Total Revenue (Financial Highlights) Analysis
2.16.3 Teva Pharmaceutical Industries SWOT Analysis
2.16.4 Teva Pharmaceutical Industries Product and Services
2.16.5 Teva Pharmaceutical Industries Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.17 Novartis
2.17.1 Novartis Details
2.17.2 Novartis Major Business and Total Revenue (Financial Highlights) Analysis
2.17.3 Novartis SWOT Analysis
2.17.4 Novartis Product and Services
2.17.5 Novartis Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.18 Boehringer Ingelheim
2.18.1 Boehringer Ingelheim Details
2.18.2 Boehringer Ingelheim Major Business and Total Revenue (Financial Highlights) Analysis
2.18.3 Boehringer Ingelheim SWOT Analysis
2.18.4 Boehringer Ingelheim Product and Services
2.18.5 Boehringer Ingelheim Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.19 ANI Pharmaceuticals
2.19.1 ANI Pharmaceuticals Details
2.19.2 ANI Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.19.3 ANI Pharmaceuticals SWOT Analysis
2.19.4 ANI Pharmaceuticals Product and Services
2.19.5 ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.20 Advaxis
2.20.1 Advaxis Details
2.20.2 Advaxis Major Business and Total Revenue (Financial Highlights) Analysis
2.20.3 Advaxis SWOT Analysis
2.20.4 Advaxis Product and Services
2.20.5 Advaxis Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.21 Spectrum Pharmaceuticals
2.21.1 Spectrum Pharmaceuticals Details
2.21.2 Spectrum Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.21.3 Spectrum Pharmaceuticals SWOT Analysis
2.21.4 Spectrum Pharmaceuticals Product and Services
2.21.5 Spectrum Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.22 Eisai
2.22.1 Eisai Details
2.22.2 Eisai Major Business and Total Revenue (Financial Highlights) Analysis
2.22.3 Eisai SWOT Analysis
2.22.4 Eisai Product and Services
2.22.5 Eisai Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.23 Nymox Pharmaceutical
2.23.1 Nymox Pharmaceutical Details
2.23.2 Nymox Pharmaceutical Major Business and Total Revenue (Financial Highlights) Analysis
2.23.3 Nymox Pharmaceutical SWOT Analysis
2.23.4 Nymox Pharmaceutical Product and Services
2.23.5 Nymox Pharmaceutical Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.24 Madrigal Pharmaceuticals
2.24.1 Madrigal Pharmaceuticals Details
2.24.2 Madrigal Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.24.3 Madrigal Pharmaceuticals SWOT Analysis
2.24.4 Madrigal Pharmaceuticals Product and Services
2.24.5 Madrigal Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.25 LIDDS
2.25.1 LIDDS Details
2.25.2 LIDDS Major Business and Total Revenue (Financial Highlights) Analysis
2.25.3 LIDDS SWOT Analysis
2.25.4 LIDDS Product and Services
2.25.5 LIDDS Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.26 Ferring
2.26.1 Ferring Details
2.26.2 Ferring Major Business and Total Revenue (Financial Highlights) Analysis
2.26.3 Ferring SWOT Analysis
2.26.4 Ferring Product and Services
2.26.5 Ferring Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.27 Takeda Pharmaceuticals
2.27.1 Takeda Pharmaceuticals Details
2.27.2 Takeda Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.27.3 Takeda Pharmaceuticals SWOT Analysis
2.27.4 Takeda Pharmaceuticals Product and Services
2.27.5 Takeda Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.28 IO THERAPEUTICS
2.28.1 IO THERAPEUTICS Details
2.28.2 IO THERAPEUTICS Major Business and Total Revenue (Financial Highlights) Analysis
2.28.3 IO THERAPEUTICS SWOT Analysis
2.28.4 IO THERAPEUTICS Product and Services
2.28.5 IO THERAPEUTICS Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
3 Sales, Revenue and Market Share by Manufacturer
3.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales and Market Share by Manufacturer (2018-2019)
3.2 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue and Market Share by Manufacturer (2018-2019)
3.3 Market Concentration Rate
3.3.1 Top 3 Benign Prostatic Hyperplasia (BPH) Medication Manufacturer Market Share in 2019
3.3.2 Top 6 Benign Prostatic Hyperplasia (BPH) Medication Manufacturer Market Share in 2019
3.4 Market Competition Trend
4 Global Market Analysis by Regions
4.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Market Share by Regions
4.1.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales and Market Share by Regions (2015-2020)
4.1.2 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue and Market Share by Regions (2015-2020)
4.2 North America Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
4.3 Europe Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
4.4 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
4.5 South America Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
4.6 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
5 North America by Country
5.1 North America Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Market Share by Country
5.1.1 North America Benign Prostatic Hyperplasia (BPH) Medication Sales and Market Share by Country (2015-2020)
5.1.2 North America Benign Prostatic Hyperplasia (BPH) Medication Revenue and Market Share by Country (2015-2020)
5.2 United States Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
5.3 Canada Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
5.4 Mexico Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
6 Europe by Country
6.1 Europe Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Market Share by Country
6.1.1 Europe Benign Prostatic Hyperplasia (BPH) Medication Sales and Market Share by Country (2015-2020)
6.1.2 Europe Benign Prostatic Hyperplasia (BPH) Medication Revenue and Market Share by Country (2015-2020)
6.2 Germany Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
6.3 UK Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
6.4 France Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
6.5 Russia Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
6.6 Italy Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
7 Asia-Pacific by Regions
7.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Market Share by Regions
7.1.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Medication Sales and Market Share by Regions (2015-2020)
7.1.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Medication Revenue and Market Share by Regions (2015-2020)
7.2 China Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
7.3 Japan Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
7.4 Korea Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
7.5 India Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
7.6 Southeast Asia Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
7.7 Australia Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
8 South America by Country
8.1 South America Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Market Share by Country
8.1.1 South America Benign Prostatic Hyperplasia (BPH) Medication Sales and Market Share by Country (2015-2020)
8.1.2 South America Benign Prostatic Hyperplasia (BPH) Medication Revenue and Market Share by Country (2015-2020)
8.2 Brazil Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
8.3 Argentina Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
9 Middle East & Africa by Countries
9.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Market Share by Country
9.1.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Sales and Market Share by Country (2015-2020)
9.1.2 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Revenue and Market Share by Country (2015-2020)
9.2 Saudi Arabia Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
9.3 Turkey Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
9.4 Egypt Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
9.5 South Africa Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
10 Market Segment by Type
10.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales and Market Share by Type (2015-2020)
10.2 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue and Market Share by Type (2015-2020)
10.3 Global Benign Prostatic Hyperplasia (BPH) Medication Price by Type (2015-2020)
11 Global Benign Prostatic Hyperplasia (BPH) Medication Market Segment by Application
11.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Application (2015-2020)
11.2 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Application (2015-2020)
11.3 Global Benign Prostatic Hyperplasia (BPH) Medication Price by Application (2015-2020)
12 Market Forecast
12.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Growth Rate (2021-2025)
12.2 Benign Prostatic Hyperplasia (BPH) Medication Market Forecast by Regions (2021-2025)
12.2.1 North America Benign Prostatic Hyperplasia (BPH) Medication Market Forecast (2021-2025)
12.2.2 Europe Benign Prostatic Hyperplasia (BPH) Medication Market Forecast (2021-2025)
12.2.3 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Medication Market Forecast (2021-2025)
12.2.4 South America Benign Prostatic Hyperplasia (BPH) Medication Market Forecast (2021-2025)
12.2.5 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Market Forecast (2021-2025)
12.3 Benign Prostatic Hyperplasia (BPH) Medication Market Forecast by Type (2021-2025)
12.3.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales Forecast by Type (2021-2025)
12.3.2 Global Benign Prostatic Hyperplasia (BPH) Medication Market Share Forecast by Type (2021-2025)
12.4 Benign Prostatic Hyperplasia (BPH) Medication Market Forecast by Application (2021-2025)
12.4.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales Forecast by Application (2021-2025)
12.4.2 Global Benign Prostatic Hyperplasia (BPH) Medication Market Share Forecast by Application (2021-2025)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
15.3 Disclaimer
15.4 About US

...

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の良性前立腺肥大症(BPH)治療薬市場2020:製造企業別、地域別、種類別、用途別、市場予測2025(Global Benign Prostatic Hyperplasia (BPH) Medication Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025)]についてメールでお問い合わせはこちらでお願いします。